Rebecca Miksad, MD

Associate Professor, Medicine

Rebecca Miksad
820 Harrison Avenue


Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).


  • Cornell University, MD
  • Harvard University, MMS/MMSc
  • Harvard School of Public Health, MPH
  • Harvard University, BA


  • Published on 1/9/2024

    Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncol Pract. 2024 Mar; 20(3):370-377. PMID: 38194619.

    Read at: PubMed
  • Published on 8/31/2023

    Guadamuz JS, Wang X, Ryals CA, Miksad RA, Snider J, Walters J, Calip GS. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022. JNCI Cancer Spectr. 2023 Aug 31; 7(5). PMID: 37707536.

    Read at: PubMed
  • Published on 6/20/2023

    Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. J Clin Oncol. 2023 Oct 20; 41(30):4729-4738. PMID: 37339389.

    Read at: PubMed
  • Published on 6/1/2023

    Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023 Jun 01; 6(6):e2316642. PMID: 37273206.

    Read at: PubMed
  • Published on 3/21/2023

    Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, Miksad RA. Association between posttreatment a-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer. 2023 Jul 01; 129(13):2064-2074. PMID: 36942492.

    Read at: PubMed
  • Published on 3/13/2023

    Liu Q, Mathur R, Xu Y, Torres AZ, Miksad RA, Liu C, Smithson H, Wang Y, Zhu H, Booth B, Huang SM, Zhi J, Sridhara R, Blumenthal GM, Larkins E, Mishra-Kalyani PS, Rivera DR, Kluetz PG, Sharon E. The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data. Clin Pharmacol Ther. 2023 May; 113(5):1139-1149. PMID: 36790088.

    Read at: PubMed
  • Published on 12/1/2022

    Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life-Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncol. 2022 Dec 01; 8(12):1847-1849. PMID: 36264566.

    Read at: PubMed
  • Published on 11/1/2022

    Jaber Chehayeb R, Hood A, Wang X, Miksad R, Schellhorn Mougalian S, Lustberg MB, Wang SY, Greenup RA, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Netw Open. 2022 Nov 01; 5(11):e2244204. PMID: 36445704.

    Read at: PubMed
  • Published on 10/4/2022

    Calip GS, Cohen A, Rohrer R, Wang X, Wang X, Webster A, Wu A, Griffith SD, Showalter TN, Miksad RA. Telemedicine use among patients with metastatic breast cancer during the COVID-19 pandemic: Differences by race, age, and region. Pharmacoepidemiol Drug Saf. 2023 Jan; 32(1):66-72. PMID: 36111444.

    Read at: PubMed
  • Published on 8/16/2022

    Coombs L, Orlando A, Wang X, Shaw P, Rich AS, Lakhtakia S, Titchener K, Adamson B, Miksad RA, Mooney K. A machine learning framework supporting prospective clinical decisions applied to risk prediction in oncology. NPJ Digit Med. 2022 Aug 16; 5(1):117. PMID: 35974092.

    Read at: PubMed

View 82 more publications: View full profile at BUMC

View all profiles